Onco-Innovations Advances ONC010 Toward Clinical Trials with Key Manufacturing Milestones

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced significant progress in the development of its lead candidate, ONC010, a small-molecule PNKP inhibitor designed to exploit DNA Damage Response (DDR) vulnerabilities in cancer cells. The company has successfully completed several key milestones, including the production of a 300-gram development batch of the active ingredient with approximately 99.3% purity, and the identification of a non-tin catalyst that could enhance impurity control in future polymer manufacturing.

The advancement of ONC010 is particularly critical because cancer cells can repair DNA damage induced by therapies, leading to resistance. By inhibiting PNKP, an enzyme involved in DNA repair, ONC010 aims to disable these repair mechanisms, thereby making cancer cells more susceptible to treatment. The nanoparticle delivery system is designed to enhance the drug's efficacy and specificity.

According to the company's latest update, ONC010 has progressed across API manufacturing, polymer optimization, analytical development, preclinical characterization, and clinical planning. The high purity achieved in the development batch underscores the feasibility of scalable production, while the novel catalyst could lead to more consistent manufacturing processes and improved product quality.

Onco-Innovations is also building a regulatory pathway in Australia for a potential First-in-Human study. During the second half of 2026, the company plans to advance bioanalytical, metabolism, ADME (absorption, distribution, metabolism, and excretion), toxicology, biodistribution, and regulatory preparation activities. These steps are essential to meet the requirements for clinical trial approval and to ensure patient safety.

The significance of this progress lies in the potential of ONC010 to address an unmet medical need in oncology. DDR inhibitors are a promising class of drugs, and PNKP is an emerging target that could broaden the scope of treatable cancers. By advancing ONC010 through preclinical development, Onco-Innovations is positioning itself to enter clinical trials, which could lead to new therapeutic options for patients.

Investors and stakeholders are closely monitoring these developments, as successful clinical translation could validate the company's platform and create value. The company's focus on rigorous preclinical characterization and regulatory preparation reflects a commitment to advancing ONC010 responsibly and efficiently.

For more information on Onco-Innovations and its pipeline, visit the company's newsroom at ibn.fm/ONNVF.